Search filters

Filters
Clear All

Phase

  • 5
  • 6
  • 15
  • 27
  • 2
  • 6
  • 67
  • 48
  • 67

Found 67 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A randomized  double-blind  placebo controlled  multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction
1 years - 99 years
All genders
A multi-center study evaluating the effects of ranolazine in subjects with class II/III/IV pulmonary hypertension on stable background therapy and persistent RV dysfunction. Study involves an observational arm and a 26-week treatment arm. At baseline (wk 0), interim (wk 13) and the conclusion of treatment period (wk 26) subjects will …
 UPCC 15518 / ANAM-17-21: A Phase 3  Randomized  Double-Blind  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
 Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure with Preserved Ejection Fraction
1 years - 99 years
All genders
Phase 1
The purpose of this study is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections, exercise capacity, left ventricular (LV) mass/fibrosis and diastolic function in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). This is a double-blind, placebo-controlled pilot randomized …
 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimers Disease
18 years - 99 years
All genders
Phase 3
BAN2401-G000-301 (Study 301) is an 18-month treatment (Core Study), multicenter, double-blind, placebo-controlled, parallel-group study in subjects with EAD (mild cognitive impairment [MCI] due to AD with intermediate likelihood/Prodromal AD or mild AD dementia) with confirmed amyloid pathology indicated by either positive amyloid load confirmed by amyloid PET assessment or CSF …
 Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction
40 years - 100 years
All genders
Although anti-retroviral therapy (ART) enhances life expectancy and overall quality of life (QoL), HIV-infected individuals are increasingly vulnerable to non-AIDS-related diseases including HIV-associated neurocognitive disorders (HAND). Inflammation is a primary mechanism in the pathogenesis of HAND and tobacco use may further exacerbate inflammation. Conversely, nicotine alone has anti-inflammatory effects suggesting …
 Padsevonil as adjunctive treatment of focal-onset seizures
18 years - 90 years
All genders
Phase 2
Observational
You are being asked to participate in this clinical research study because you have epilepsy associated with focal onset seizures (or sometimes called partial seizures), and your seizures are not well controlled with your current treatment. Seizures are caused by abnormal electrical disturbances in the brain. Focalonset seizures occur when …
61 - 67 of 67